4-溴异吲哚啉-1-酮 | 337536-15-9

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 4-溴异吲哚啉-1-酮
• 中文别名: 1H-异吲哚-1-酮,4-溴-2,3-二氢
• 英文名称: 4-bromoisoindolin-1-one
• 英文别名: 4-bromo-2,3-dihydro-isoindol-1-one；4-bromo-2,3-dihydroisoindol-1-one
• CAS: 337536-15-9
• 化学式: C₈H₆BrNO
• mdl: MFCD09701286
• 分子量: 212.046
• InChiKey: TYRICULVJRGSTL-UHFFFAOYSA-N

物化性质

• 沸点：
  448.9±45.0 °C(Predicted)
• 密度：
  1.666

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933790090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Bromoisoindolin-1-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromoisoindolin-1-one
CAS number: 337536-15-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6BrNO
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴异吲哚啉-1-酮 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 硝酸 、 palladium diacetate 、 sodium carbonate 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 水 为溶剂， 反应 3.0h， 生成 7-amino-4-phenylisoindolin-1-one
  参考文献：
  名称：

  COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

  摘要：

  提供的化合物是一种TNIK（Traf2-和NCK相互作用激酶）、IKKε（I-κB激酶ε）和TBK1（TANK结合激酶1）抑制剂的化合物；根据本发明的化合物有效抑制TNIK、IKKε和TBK1，因此不仅可用作抗癌剂治疗各种癌症，包括结直肠癌、乳腺癌、中枢神经系统癌、结肠癌、非小细胞肺癌、肾癌、前列腺癌、卵巢癌、子宫癌、胃癌、肝癌、皮肤癌、肺癌、脑癌、膀胱癌、食管癌、胰腺癌、甲状腺癌、头颈癌、鳞状细胞癌、骨肉瘤、B细胞或T细胞淋巴瘤、急性或慢性白血病和多发性骨髓瘤，还可用作慢性炎症的治疗剂。

  公开号：

  US20160311772A1
• 作为产物：
  描述：

  3-溴-2-甲基苯(甲)酰氯 在 ammonium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 三乙胺 、 过氧化苯甲酰 作用下， 以 四氢呋喃 、 苯 为溶剂， 生成 4-溴异吲哚啉-1-酮
  参考文献：
  名称：

  Isoindolinone ureas: a novel class of KDR kinase inhibitors

  摘要：

  A series of substituted isoindolinone ureas was prepared and evaluated for enzymatic and cellular inhibition of KDR kinase activity. Several of these analogs, such as 14c, are potent inhibitors of KDR both enzymatically (<50nM) and cellularly (less than or equal to100 nM). A 3D KDR/CDK2/MAP kinase overlay model with several structurally related tyrosine kinase inhibitors was used to predict the binding interactions of the isoindolinone ureas with the KDR active site. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.041

文献信息

• Certain pyrazoline derivatives with kinase inhibitory activity
  申请人：Adams Ruth S.

  公开号：US20080171754A1

  公开（公告）日：2008-07-17

  The present invention provides certain pyrazoline compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions and methods of using the compositions in the treatment of various diseases.

  本发明提供了某些吡唑啉化合物，可用作蛋白激酶的抑制剂。该发明还提供了药物组合物和使用这些组合物治疗各种疾病的方法。
• [EN] ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSES D'ISOINDOLINE-1-ONE UTILISES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ABBOTT LAB

  公开号：WO2004108672A1

  公开（公告）日：2004-12-16

  Compounds having the formula, (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds and compositions containing the compounds.

  具有公式(I)的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还公开了制造这些化合物的方法以及包含这些化合物的组合物。
• Comprehensive structure-activity-relationship of azaindoles as highly potent FLT3 inhibitors
  作者：Sebastian H. Grimm、Berend Gagestein、Jordi F. Keijzer、Nora Liu、Ruud H. Wijdeven、Eelke B. Lenselink、Adriaan W. Tuin、Adrianus M.C.H. van den Nieuwendijk、Gerard J.P. van Westen、Constant A.A. van Boeckel、Herman S. Overkleeft、Jacques Neefjes、Mario van der Stelt

  DOI：10.1016/j.bmc.2019.01.006

  日期：2019.3

  Acute myeloid leukemia (AML) is characterized by fast progression and low survival rates, in which Fms-like tyrosine kinase 3 (FLT3) receptor mutations have been identified as a driver mutation in cancer progression in a subgroup of AML patients. Clinical trials have shown emergence of drug resistant mutants, emphasizing the ongoing need for new chemical matter to enable the treatment of this disease

  急性髓细胞性白血病（AML）的特征是进展快，生存率低，其中已将Fms样酪氨酸激酶3（FLT3）受体突变确定为AML患者亚组中癌症进展的驱动程序突变。临床试验已显示出耐药突变体的出现，强调了对新化学物质的持续需求，以使该疾病得以治疗。在这里，我们介绍了已知的PKA抑制剂异喹啉磺酰胺H-89作为FLT3抑制剂的类似物的发现和拓扑结构-活性关系（SAR）研究。令人惊讶地，我们发现SAR与在PKA中观察到的H-89的结合模式不一致。匹配的分子对分析导致鉴定出高活性的亚纳摩尔氮杂吲哚作为新型的FLT3抑制剂。
• Isoindolinone kinase inhibitors
  申请人：Curtin L. Michael

  公开号：US20050026976A1

  公开（公告）日：2005-02-03

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有该公式的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还公开了制造这些化合物的方法、包含这些化合物的组合物以及使用这些化合物的治疗方法。
• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS DESTINÉS À LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262684A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开披露的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。披露的化合物可用于减少含有p53突变的癌症的进展。